Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the appointment of Matthew Shields as Executive Vice
President of Teva Global Operations (TGO), the Company’s
manufacturing and supply division, effective June 3, 2024. Mr.
Shields succeeds Eric Drapé, who is leaving after 11 years with the
Company, including more than four years as Executive Vice
President, Global Operations. Mr. Shields will be a member of
Teva’s Executive Leadership Team and report directly to President
and CEO Richard Francis. He will be based in Teva’s U.S.
headquarters in Parsippany, NJ.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240515380320/en/
MATTHEW SHIELDS APPOINTED TO EXECUTIVE
VICE PRESIDENT, TEVA GLOBAL OPERATIONS (Photo: Business Wire)
Mr. Shields joins Teva with a track record over a 25-plus year
career in the global biopharmaceutical and animal health
industries. As an engineer by trade, Mr. Shields brings significant
experience at every stage of the manufacturing and supply process.
Most recently, Mr. Shields served as Senior Vice President for
Animal Health Manufacturing for Merck, known as MSD Animal Health
outside of the United States and Canada, where he oversaw
end-to-end manufacturing, supply chain, procurement, and process
development. Prior to Merck, he led Specialty Care Manufacturing,
Engineering, and Operational Excellence for Sanofi. Mr. Shields
spent much of his early career at Amgen, where held a variety of
leadership roles in Operations.
Richard Francis, Teva's President and CEO stated: “I’m thrilled
to welcome a transformational leader of Matthew’s caliber to the
executive team at Teva. Matthew brings a wealth of experience in
health operations that are critical to fulfilling our purpose by
enabling Teva to execute on our promises to patients and healthcare
systems around the world. Matthew is ideally positioned to lead our
TGO organization through the next phase of our Pivot to Growth
journey.”
Mr. Francis added: “As we have intensified our efforts to best
position Teva for future success through our Pivot to Growth
strategy, Eric Drapé has played a key role in strengthening our
operations network. During his tenure leading TGO, the organization
has made tremendous strides serving patients by standardizing
processes, increasing agility, and improving our operating margin.
I would like to thank Eric for his many contributions to Teva and
wish him all the best as he embarks on a new and exciting phase in
his life.”
Mr. Shields stated: “Teva is clearly a company with incredible
potential based on the early progress of its Pivot to Growth
strategy, and its tremendous heritage in manufacturing important
medicines serving the needs of patients around the world. I’m
honored to take on this critical role, and eager to begin working
with the talented team in Teva Global Operations, and my colleagues
across the Company, to deliver on our inspiring purpose.”
Matthew Shields Bio
Mr. Shields is a manufacturing and supply chain leader with more
than 25 years of experience in the biopharmaceuticals and animal
health industries. He’s held leadership roles at Merck Animal
Health, Sanofi, and Amgen.
He joins Teva from Merck Animal Health where he served as Senior
Vice President for Manufacturing with responsibility for supporting
$5.6 billion in annual sales. During his time at Merck, Mr. Shields
also oversaw the Supply Chain, Procurement, and Process Development
organizations. His leadership was instrumental in navigating
challenging global issues and business integration efforts, while
driving improvements in the company’s operations network and
delivering significant savings.
Prior to Merck, Mr. Shields was a senior leader at Sanofi, first
serving as Head of Engineering and Operational Excellence for the
company’s Biologics organization. In that role, he led a lean
transformation program resulting in substantial cost savings and
operational efficiencies. Later he became Global Head of Sanofi’s
Specialty Care Manufacturing organization with a focus on enabling
the successful launches of Dupixent® and Praluent®, while also
overseeing the commissioning and startup of Sanofi’s first
digitally enabled continuous manufacturing facility.
Mr. Shields spent a significant portion of his career with
Amgen, holding series of increasingly responsible leadership roles
including Head of Global Raw Material Supplier Relationships,
Executive Director & Plant Manager in Singapore, and Executive
Director of Manufacturing. Notable achievements include overseeing
the transition of Amgen’s manufacturing of the future program from
R&D to Operations, the start-up of its manufacturing site of
the future in Singapore, and leading capacity and throughput
improvements of their large-scale biologics manufacturing facility
in Rhode Island.
Mr. Shields received his undergraduate degree in Chemical
Engineering & Materials Science Engineering from the University
of Connecticut and an MBA from Bryant University in Rhode Island.
He currently serves on the board of the National Association of
Manufacturers.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global pharmaceutical leader with a category-defying portfolio,
harnessing our generics expertise and stepping up innovation to
continue the momentum behind the discovery, delivery, and expanded
development of modern medicine. For over 120 years, Teva's
commitment to bettering health has never wavered. Today, the
company’s global network of capabilities enables its ~37,000
employees across 58 markets to push the boundaries of scientific
innovation and deliver quality medicines to help improve health
outcomes of millions of patients every day. To learn more about how
Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to: our business and operations
in general, including our ability to attract, hire, integrate and
retain highly skilled personnel; our ability to successfully
compete in the marketplace, including our ability to successfully
execute our Pivot to Growth strategy, including to expand our
innovative and biosimilar medicines pipeline and profitably
commercialize the innovative medicines and biosimilar portfolio,
whether organically or through business development, and to sustain
and focus our portfolio of generics medicines; and other factors
discussed in this press release, in our quarterly report on Form
10-Q for the first quarter of 2024, and in our Annual Report on
Form 10-K for the year ended December 31, 2023, including in the
sections captioned "Risk Factors”. Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515380320/en/
IR Ran Meir +1 (267) 468-4475 Yael Ashman +972 (3) 914
8262 Sanjeev Sharma +1 (973) 658 2700 Media Kelley Dougherty
+1 (973) 832-2810 Eden Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Jan 2025 to Feb 2025
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Feb 2024 to Feb 2025
